Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report

[1]  J. Thachil,et al.  Management of pregnancy in type 3 von Willebrand disease with alloantibodies , 2018, British journal of haematology.

[2]  M. Franchini,et al.  Alloantibodies in von Willebrand Disease , 2017, Seminars in Thrombosis and Hemostasis.

[3]  C. Leissinger,et al.  Acquired hemophilia A: Updated review of evidence and treatment guidance , 2017, American journal of hematology.

[4]  S. Skov,et al.  Non‐genetic risk factors in haemophilia A inhibitor management – the danger theory and the use of animal models , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Oldenburg,et al.  Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A , 2016, Thrombosis and Haemostasis.

[6]  R. Tait,et al.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology , 2014, British journal of haematology.

[7]  P. Mannucci,et al.  Alloantibodies in von Willebrand disease. , 2013, Blood.

[8]  A. Biswas,et al.  Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients , 2012, Thrombosis and Haemostasis.

[9]  H. Platokouki,et al.  The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  R. Zotz,et al.  Use of Recombinant Factor VIIa in Inherited and Acquired von Willebrand Disease , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[11]  M Morfini,et al.  Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  M. Wolf,et al.  Multi‐therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease , 2003, Journal of thrombosis and haemostasis : JTH.

[13]  A. Houllier,et al.  Mapping and Functional Studies of Two Alloantibodies Developed in Patients with Type 3 von Willebrand Disease , 2000, Thrombosis and Haemostasis.

[14]  J. Batlle,et al.  Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction , 1997, Annals of Hematology.

[15]  A. Federici,et al.  Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. , 1995, The Journal of laboratory and clinical medicine.

[16]  A. Federici,et al.  Antibodies to von Willebrand factor in von Willebrand disease. , 1995, Advances in experimental medicine and biology.

[17]  P. Mannucci,et al.  Life‐threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor , 1987, European journal of haematology.

[18]  P. Mannucci,et al.  Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand's disease. , 1984, Progress in clinical and biological research.

[19]  P. Mannucci,et al.  Familial incidence of precipitating antibodies in von Willebrand's disease: a study of four cases. , 1979, The Journal of laboratory and clinical medicine.

[20]  Letter: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.